Method for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite
The present invention provides a method for treating wounds and diseases in mammals, caused by mammalian cells involved in an inflammatory response, by altering indigenous in vivo levels of peroxynitrous acid, and salts thereof. The method comprises contacting the mammalian cells with a therapeutically effective amount of a reactive oxygen species mediator, wherein the reactive oxygen species mediator is selected from the group consisting of pyruvates, pyruvate precursors, α-keto acids having four or more carbon atoms, precursors of α-keto acids having four or more carbon atoms, and the salts thereof, wherein mediation of reactive oxygen species results in mediation of peroxynitrous acid. The present invention further provides a pharmaceutical composition for treating wounds and diseases in mammals, caused by mammalian cells involved in an inflammatory response, by altering indigenous in vivo levels of peroxynitrous acid, and salts thereof.
1. A method for treating dermabrasions, burns, dry skin and cold sores, caused by an inflammatory response in mammalian cells, by altering the indigenous in vivo levels of peroxynitrous acid, and salts therein, comprising contacting the mammalian cells with a therapeutically effective amount of a reactive oxygen species mediator, wherein the reactive oxygen species mediator is a mixture of a pyruvate or a pyruvate precursor and an α-keto acid selected from the group consisting of α-keto-glutaric acid, α-keto-isovaleric acid, their precursors, and the salts thereof, wherein the mediation of the reactive oxygen species results in mediation of peroxynitrous acid.
2. A method for treating dermabrasions, burns, dry skin and cold sores in mammals, caused by mammalian cells involved in an inflammatory response, by protecting a therapeutic anti-viral agent selected from the group consisting of acyclovir, by altering indigenous in vivo levels of peroxynitrous acid, and salts thereof, comprising contacting the mammalian cells with a therapeutically effective amount of a reactive oxygen species mediator, wherein the reactive oxygen species mediator is a mixture of a pyruvate or a pyruvate precursor and an α-keto acid selected from the group consisting of α-keto-glutaric acid, α-keto-isovaleric acid, their precursors and the salts thereof, wherein mediation of the reactive oxygen species results in mediation of peroxynitrous acid.
3. A method for treating dermabrasions, burns, dry skin and cold sores in mammals, caused by mammalian cells involved in an inflammatory response, by protecting an anti-bacterial agent comprising mupirocin by altering indigenous in vivo levels of peroxynitrous acid, and salts thereof, comprising contacting the mammalian cells with a therapeutically effective amount of a reactive oxygen species mediator, wherein the reactive oxygen species mediator is a mixture of a pyruvate or a pyruvate precursor and an α-keto acid selected from the group consisting of α-keto-glutaric acid, α-keto-isovaleric acid, their precursors and the salts thereof, wherein mediation of the reactive oxygen species results in mediation of peroxynitrous acid.
4. A method for treating dermabrasions, burns, dry skin and cold sores in mammals, caused by mammalian cells involved in an inflammatory response, by protecting a therapeutic agent selected from the group consisting doxorubicin, clotrimazol, and hydrocortisone by altering indigenous in vivo levels of peroxynitrous acid, and salts thereof, comprising contacting the mammalian cells with a therapeutically effective amount of a reactive oxygen species mediator, wherein the reactive oxygen species mediator is a mixture of a pyruvate or a pyruvate precursor and an α-keto acid selected from the group consisting of a α-keto-glutaric acid, α-keto-isovaleric acid, their precursors and the salts thereof, wherein mediation of the reactive oxygen species results in mediation of peroxynitrous acid.
5. A method for treating dermabrasions, burns, dry skin and cold sores in mammals, caused by mammalian cells involved in an inflammatory response, by protecting an anti-bacterial therapeutic agent comprising a mixture of bacitracin, neomycin, and polymixin, by altering indigenous in vivo levels of peroxynitrous acid, and salts thereof, comprising contacting the mammalian cells with a therapeutically effective amount of a reactive oxygen species mediator, wherein the reactive oxygen species mediator is a mixture of a pyruvate or a pyruvate precursor and an α-keto acid selected from the group consisting of α-keto-glutaric acid, α-keto-isovaleric acid, their precursors and the salts thereof, wherein mediation of the reactive oxygen species results in mediation of peroxynitrous acid.